Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

18 Oct 2024

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

26 Sep 2024

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

16 Sep 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

26 Jun 2024

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

4 Jun 2024

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

3 Jun 2024

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

3 Jun 2024

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

3 Jun 2024

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China

1 Jun 2024

ISCO 2023